Rwanda’s President Paul Kagame has said that end-to-end production of mRNA vaccines is possible in Africa, thanks to innovations in engineering being undertaken by BioNTech and its partners, among others.
This trend is set to have wide implications for the feasibility of all types of pharmaceutical production in Africa in the years ahead.
“The necessary partnerships are in place to make this happen. Around the table here, we have the European Union, the European Investment Bank, the World Health Organization, and Africa CDC.” Kagame said.
“Other organizations, such as the Mastercard Foundation and the International Finance Corporation, are also making critical contributions.”